代谢健康型肥胖与非酒精性脂肪性肝病患病率的相关性

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (6): 837-841.

代谢健康型肥胖与非酒精性脂肪性肝病患病率的相关性

许可, 胡珦, 虞伟慧, 杨丽娟, 顾雪疆^*

温州医科大学附属第一医院内分泌科, 浙江温州 325015

收稿日期:2021-03-23 修回日期:2021-04-16 出版日期:2021-06-05 发布日期:2021-05-31
通讯作者: ^* guxuejiang@wmu.edu.cn
基金资助:
浙江省教育厅一般项目(Y201942253);浙江省自然科学基金(LY20H070003);浙江省重点研发计划(2021C03069)

Relationship between metabolically healthy obesity and the prevalence of non-alcoholic fatty liver disease

XU Ke, HU Xiang, YU Wei-hui, YANG Li-juan, GU Xue-jiang^*

Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China

Received:2021-03-23 Revised:2021-04-16 Online:2021-06-05 Published:2021-05-31
Contact: ^* guxuejiang@wmu.edu.cn

摘要/Abstract

摘要： 目的调查代谢正常肥胖在非酒精性脂肪性肝病(NAFLD)中的作用。方法 2011至2012年对温州市4个社区的4 757名参与者进行了横断面调查。通过问卷调查、体格检查、实验室检查等进行数据收集,多元logistic回归分析用于综合分析NAFLD的危险因素。结果代谢健康型肥胖1 068人(22.4％),NAFLD的患病率为43.5%,在肥胖的各个表型中,占比从高到低分别为代谢异常肥胖(MUO)、代谢异常非肥胖(MUNO)、代谢健康肥胖(MHO)和代谢健康非肥胖(MHNO)。通过腰围和BMI定义肥胖,MHO人群患NAFLD的风险较MHNO分别高3.38倍(95% CI:2.13~5.37)和4.69倍(95% CI:3.01~7.16)。结论 MHO与中国人群NAFLD患病风险增高相关,肥胖人群无论代谢健康与否都应积极筛查NAFLD。

关键词: 代谢健康型肥胖, 非酒精性脂肪性肝病, 腰围, BMI

Abstract: Objective To investigate the role of metabolically normal obesity in non-alcoholic fatty liver disease(NAFLD). Methods From 2011 to 2012, a cross-section survey with 4 757 participants enrolled from four communities in Wenzhou was conducted. Data collection was conducted through questionnaire survey, physical examination, laboratory examination, and multiple logistic regression analysis was used to comprehensively identify the risk factors of NAFLD. Results 1 068 individuals(22.4%) were diagnosed as metabolically healthy obesity. The prevalence of NAFLD was 43.5%. Among the various obesity phenotypes, the proportions ranked from high to low were metabolically unhealthy obese(MUO), metabolically unhealthy nonobese(MUNO), metabolically healthy obese(MHO) and metabolically healthy nonobese(MHNO). Obesity was defined by waist circumference and BMI, the risk of NAFLD in MHO population was 3.38 times(95% CI:2.13-5.37) and 4.69 times(95% CI:3.01-7.16) higher than that of MHNO, respectively. Conclusions MHO is associated with an increased risk of NAFLD in the Chinese population. It is necessary to screen for NAFLD in obese subjects regardless state of metabolic health.

Key words: metabolically healthy obesity, non-alcoholic fatty liver disease, waist circumference, BMI

中图分类号:

R589.2

许可, 胡珦, 虞伟慧, 杨丽娟, 顾雪疆. 代谢健康型肥胖与非酒精性脂肪性肝病患病率的相关性[J]. 基础医学与临床, 2021, 41(6): 837-841.

XU Ke, HU Xiang, YU Wei-hui, YANG Li-juan, GU Xue-jiang. Relationship between metabolically healthy obesity and the prevalence of non-alcoholic fatty liver disease[J]. Basic & Clinical Medicine, 2021, 41(6): 837-841.

参考文献

[1] Rinella ME. Nonalcoholic fatty liver disease: a systematic review[J]. JAMA, 2015, 313: 2263-2273.
[2] Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J]. Gut, 2017, 66: 1138-1153.
[3] Allen AM, Thernaeu TM, Larson JJ, et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study[J]. Hepatology, 2018, 67: 1726-1736.
[4] Eslam M, Newsome PN, Sarin SK, et al. A new defini-tion for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. Hepatology, 2020, 73: 202-209.
[5] Lynch LA, O'connell JM, Kwasnik AK, et al. Are natural killer cells protecting the metabolically healthy obese patient?[J]. Obesity(Silver Spring, Md), 2009, 17: 601-605.
[6] Targher G, Byrne CD. Obesity: Metabolically healthy obesity and NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2016, 13: 442-444.
[7] Ning G. Risk evaluation of cancers in Chinese diabetic individuals: a longitudinal study[J]. Diabetes, 2012, 4: 172-173.
[8] Zimmet P, K George MMA, Serrano Rios M. A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results[J]. Rev Esp Cardiol, 2005, 58: 1371-1376.
[9] Rey-L PezJ P, DE Rezende LF, Pastor-Valero M, et al. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used[J]. Obes Rev, 2014, 15: 781-790.
[10] Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity[J]. Circulation, 2009, 120: 1640-1645.
[11] Leitzmann MF, Moore SC, Koster A, et al. Waist circumference as compared with body-mass index in predicting mortality from specific causes[J]. PLoS One, 2011, 6: e18582.doi:10.1371/journal.pone.0018582.
[12] Bl Her M. Metabolically healthy obesity[J]. Endocr Rev, 2020, 41: 405-420.
[13] Wu LM, He H, Chen G, et al. Associations between obesity and metabolic health with nonalcoholic fatty liver disease in elderly Chinese[J]. Hepatobiliary Pancreat Dis Int, 2020, 19: 252-257.
[14] Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications[J]. Hepatology, 2010, 51: 679-689.
[15] Soriguer F, Guti Rrez-Repiso C, Rubio-Mart NE, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study[J]. J Clin Endocrinol Metab, 2013, 98: 2318-2325.